⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL752954 | 0.67 | — | — | |
| SCHEMBL8445903 | 0.62 | — | — | |
| SCHEMBL2041363 | 0.62 | — | — | |
| SCHEMBL9332575 | 0.62 | — | — | |
| SCHEMBL16709474 | 0.61 | SMPD3 (0.30) | — | |
| SCHEMBL9885812 | 0.59 | — | — | |
| SCHEMBL1543317 | 0.57 | — | — | |
| SCHEMBL700364 | 0.56 | — | — | |
| SCHEMBL333295 | 0.56 | — | — | |
| SCHEMBL31656609 | 0.53 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3983402-B1 | 1-((S)-1-(3-CHLORO-5-FLUORO-2-((4-(1H-PYRAZOL-1-YL)-2-METHYLQUINOLIN-8-YLOXY)METHYL)PHENYL)ETHYL)-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ (BK) B2 RECEPTOR ANTAGONIST FOR TREATING SKIN DISEASES | PHARVARIS GMBH (CH) | 2023-08-16 | — | — | EP | disclosed |
| US-20230212186-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | NURIX THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| EP-3956326-B1 | (R)-3-(3-CHLORO-5-FLUORO-2-((4-(1H-PYRAZOL-1-YL)-2-METHYLQUINOLIN-8-YLOXY)METHYL)PHENYL)MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ (BK) B2 RECEPTOR ANTAGONIST FOR TREATING SKIN DISEASES | PHARVARIS GMBH (CH) | 2023-06-28 | — | — | EP | disclosed |
| US-11530229-B2 | Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof | NURIX THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| EP-3998259-A1 | NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS | Pharvaris Netherlands B.V. (NL) | 2022-05-18 | — | — | EP | disclosed |
| EP-3713928-B1 | NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS | PHARVARIS NETHERLANDS B V (NL) | 2022-01-12 | — | — | EP | disclosed |
| US-20210053986-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | NURIX THERAPEUTICS, INC. | 2021-02-25 | — | — | US | disclosed |
| WO-2020234480-A1 | (R)-3-(CHLORO-5-FLUORO-2-((4-(1H-PYRAZOL-1-YL)-2-METHYLQUINOLIN-8-YLOXY)METHYL)PHENYL)MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ (BK) B2 RECEPTOR ANTAGONIST FOR TREATING SKIN DISEASES | PHARVARIS GMBH (CH) | 2020-11-26 | — | — | WO | disclosed |
| WO-2019101906-A1 | NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS | PHARVARIS B.V. (NL) | 2019-05-31 | — | — | WO | disclosed |